Tofacitinib

Common brands: Xeljanz Xr, Xeljanz, Methotrexate, Rasuvo, Otrexup

Top reporter: Pfizer Laboratories Div Pfizer Inc

Folate Analog Metabolic Inhibitor [EPC]Tumor Necrosis Factor Blocker [EPC]Corticosteroid [EPC]Antirheumatic Agent [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
182,680
Total Reports
77,994
Serious Reports
8,918
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (4.88%)

Patient Demographics

Male
33,876
Female
139,017

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Tofacitinib.

# Reaction Reports % of Total
1 DRUG INEFFECTIVE 43,682
11.4%
2 PAIN 25,882
6.7%
3 ARTHRALGIA 19,814
5.2%
4 CONDITION AGGRAVATED 19,599
5.1%
5 RHEUMATOID ARTHRITIS 18,924
4.9%
6 FATIGUE 16,715
4.4%
7 OFF LABEL USE 14,971
3.9%
8 JOINT SWELLING 14,574
3.8%
9 HEADACHE 13,533
3.5%
10 RASH 12,041
3.1%
11 DRUG INTOLERANCE 11,824
3.1%
12 MALAISE 10,616
2.8%
13 PAIN IN EXTREMITY 10,355
2.7%
14 ABDOMINAL DISCOMFORT 10,270
2.7%
15 NAUSEA 10,045
2.6%
16 DIARRHOEA 9,789
2.6%
17 PERIPHERAL SWELLING 9,760
2.5%
18 ALOPECIA 9,350
2.4%
19 MUSCULOSKELETAL STIFFNESS 9,323
2.4%
20 SYNOVITIS 9,292
2.4%
21 SWELLING 9,272
2.4%
22 ARTHROPATHY 9,223
2.4%
23 NASOPHARYNGITIS 8,809
2.3%
24 TREATMENT FAILURE 8,628
2.2%
25 DRUG HYPERSENSITIVITY 8,441
2.2%
26 CONTRAINDICATED PRODUCT ADMINISTERED 8,379
2.2%
27 HYPERSENSITIVITY 8,037
2.1%
28 INFECTION 7,785
2.0%
29 HEPATIC ENZYME INCREASED 7,775
2.0%
30 SYSTEMIC LUPUS ERYTHEMATOSUS 7,005
1.8%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.